LONAFARNIB ORAL ADMINISTRATION TO MICE

Recommendations from the laboratory of Francis Collins, MD, PhD; please also refer to Capell BC, et al., A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA. 2008 Oct 14;105(41):15902-7. PMID 18838683

In the above study, lonafarnib dough was formulated using 450 mg/kg of lonafarnib in transgenic dough (http://www.bio-serv.com/canine_special_needs/s3472.html), mixed thoroughly for >20 minutes, kneading with food coloring indicator.

This dosage is the maximum oral intake recommended. This dosage is very near the maximum tolerated dose of 100 mg/kg if lonafarnib were given by oral gavage.

Feed 5 g lonafarnib transgenic dough daily. Record any uneaten dough the next morning prior to the next feeding. The mice generally eat >90% of the dough, if not all.

Place the food on top of bedding in a small, plastic weigh boat with a shallow lip daily in the morning. As mice age and exhibit kyphosis, they may not be able to reach the dough if not placed on floor level.

For additional questions, or to expand upon these recommendations for the research community, please contact The Progeria Research Foundation Cell and Tissue Bank

Wendy Norris
wnorris@lifespan.org
401-274-1122 x48063

Disclaimer

This protocol for administration of lonafarnib to mice for in vivo assays is based on recommendations from the laboratory of Francis Collins, MD, PhD. The Progeria Research Foundation does not guarantee that this protocol will be effective for other laboratories.

Revision date: July 26, 2019
Progeria Research Foundation